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Abstract
Purpose: Functional-guided radiation therapy (RT) plans have the potential to limit damage to 
normal tissue and reduce toxicity. Although functional imaging modalities have continued to 
improve, a limited understanding of the functional response to radiation and its application to 
personalized therapy has hindered clinical implementation. The purpose of this study was to 
retrospectively model the longitudinal, patient-specific dose-function response in non-small cell 
lung cancer patients treated with RT to better characterize the expected functional damage in 
future, unknown patients.
Methods and Materials: Perfusion single-photon emission computed tomography/computed 
tomography scans were obtained at baseline (n = 81), midtreatment (n = 74), 3 months post-
treatment (n = 51), and 1 year post-treatment (n = 26) and retrospectively analyzed. Patients were 
treated with conventionally fractionated RT or stereotactic body RT. Normalized perfusion single-
photon emission computed tomography voxel intensity was used as a surrogate for local lung 
function. A patient-specific logistic model was applied to each individual patient’s dose-function 
response to characterize functional reduction at each imaging time point. Patient-specific model 
parameters were averaged to create a population-level logistic dose-response model.
Results: A significant longitudinal decrease in lung function was observed after RT by analyzing 
the voxelwise change in normalized perfusion intensity. Generated dose-function response models 
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represent the expected voxelwise reduction in function, and the associated uncertainty, for an 
unknown patient receiving conventionally fractionated RT or stereotactic body RT. Differential 
treatment responses based on the functional status of the voxel at baseline suggest that initially 
higher functioning voxels are damaged at a higher rate than lower functioning voxels.
Conclusions: This study modeled the patient-specific dose-function response in patients with 
non-small cell lung cancer during and after radiation treatment. The generated population-level 
dose-function response models were derived from individual patient assessment and have the 
potential to inform functional-guided treatment plans regarding the expected functional lung 
damage. This type of patient-specific modeling approach can be applied broadly to other 
functional response analyses to better capture intrapatient dependencies and characterize 
personalized functional damage.
Introduction
Functional-guided radiation therapy (RT) has long been hypothesized to improve patient 
outcome (1–8). By quantifying perfusion and ventilation in normal lung tissue, a patient’s 3-
dimensional functional lung distribution can be incorporated into treatment planning to 
personalize radiation exposure (9–12). This personalization of treatment is especially 
important in patients with non-small cell lung cancer (NSCLC), who are known to have 
comorbidities and functional lung defects that change during the course of fractionated RT 
(13–16). Recent clinical studies have shown significant differences between anatomic-and 
functional-guided radiation treatment plans using a variety of functional imaging modalities, 
such as single-photon emission computed tomography (SPECT) (17–20), 4-dimensional 
computed tomography (CT) (21–24), and hyperpolarized magnetic resonance imaging (25, 
26). Although preliminary studies have predicted toxicity reduction using functional-guided 
RT (27, 28), further work is still required to explicitly understand normal-tissue dose-
function response and its effect on radiation-induced lung toxicity (RILT) incidence.
Perfusion SPECT/CT imaging provides a quantitative measure of pulmonary function such 
that normalized intensities within each lung voxel are representative of local vascular 
concentrations (29, 30). In 1994, Boersma et al first proposed using a logistic model to 
describe dose-function response (30). Because of the observed high variation in patient-to-
patient dose response, Marks et al used a voxel-weighted average to determine composite 
perfusion loss (31). These studies provided the foundation for longitudinal quantification of 
functional lung using SPECT/CT imaging (1, 2), and the basis of these methodologies has 
been applied extensively to characterize dose-function response for various treatments, time 
points, and regions of the lung (32–37). Yet, most normal-tissue complication probability 
models currently used to assess risk of RILT rely on volumetric dose metrics that do not 
account for the heterogeneous distribution of functional lung (38–42). Although dose-
volume metrics are important determinants of RILT incidence, recent evidence suggests 
functional information can provide additional benefit in assessing and predicting treatment 
response (43, 44). Ideally, a patient’s risk of developing toxicity could be predicted by 
quantifying the expected cumulative functional lung damage for a given radiation treatment 
plan. However, enhanced modeling methods are still needed to accurately characterize lung 
function response and to facilitate clinical implementation of personalized RT.
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The purpose of this study was to quantify the longitudinal dose-function response in patients 
with NSCLC treated with conventionally fractionated RT and stereotactic body RT (SBRT). 
A patient-specific modeling approach was applied to retrospectively characterize each 
patient’s functional change, using perfusion SPECT/CT. Individual patient models were then 
used to derive a population-level model that best represents the expected dose-function 
response in a new patient. The model was further segmented by functional categorization at 
baseline to enhance the prediction of functional lung damage based on an individual’s 
pretreatment condition.
Methods and Materials
Study population
A total of 81 patients with histologically verified NSCLC were enrolled in an institutional 
review board-approved study and retrospectively analyzed. Written informed consent was 
obtained from all patients. Patients were treated with conventionally fractionated 3-
dimensional conformal RT, with (n = 47) or without (n = 13) concurrent chemotherapy, or 
with SBRT (n = 21). A summary of the patient, disease, and treatment characteristics of the 
cohort is presented in Table 1.
SPECT imaging
Perfusion SPECT images of the lung were obtained at 4 separate time points: (1) pre-
treatment; (2) mid-treatment (Mid-Tx); (3) 3 months post-treatment (3Month Post-Tx); and 
(4) 1 year post-treatment (1Year Post-Tx). SPECT imaging was performed by using a dual-
head SPECT/CT system (Symbia T6, Siemens Medical Solutions, Malvern, PA) with the 
patient immobilized in the supine treatment position using a standard thorax support device 
for reproducibility. Each patient was first scanned for pulmonary ventilation mapping by 
inhaling aerosolized99m Tc-diethylenetriaminepentaacetic acid from an 1850 MBq reservoir. 
Pulmonary perfusion was subsequently scanned after intravenous injection of 185 MBq 
of99mTc-labeled macroaggregated albumin particles.
SPECT scans were obtained with a noncircular orbit over a 360° arc in 60 projections and 
128 frames (19 s/frame, 3° increments, 128 pixels × 128 pixels, ∼3. 5 mm × ∼3.5 mm × 2 
mm) by using the stop-and-shoot mode. The SPECT images were reconstructed by initially 
applying attenuation and scatter correction and subsequently implementing a 3-dimensional 
ordered subset expectation-maximization iterative reconstruction with resolution, scatter, 
and attenuation corrections.
CT-based simulation and treatment planning
Simulation CT scans were obtained for each patient, with patients in the supine position, 
before treatment. Data were accrued over a 6-year period (2007–2013). Early in the study 
period, patients were assessed for motion through analysis of inhale and exhale CT scans. 
As the study progressed, 4-dimensional CT was incorporated for motion assessment. 
Patients with extensive motion were prescribed breath-hold treatments, and all free-
breathing patients were treated with an internal target volume approach. The Eclipse 
Analytical Anisotropic Algorithm (Varian Medical Systems, Palo Alto, CA) photon dose 
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model was used to retrospectively calculate the delivered dose to each voxel in the CT 
matrix (512 pixels × 512 pixels, 0.98 mm × 0.98 mm × 3 mm). For each patient, the 
calculated dose in each normal lung voxel was then corrected to the nominal dose equivalent 
per 2 Gy fraction (EQD2) using the linear quadratic model with an α/β ratio of 2.5 Gy (45). 
Lung structures were contoured as part of treatment planning and edited according to a 
thoracic atlas (46). Normal lung tissue was defined as all voxels within the lungs excluding 
the gross tumor volume.
SPECT registration
SPECT scans were available for 81 patients at baseline, 75 at Mid-Tx, 52 at 3Month Post-
Tx, and 28 at 1Year Post-Tx. For a given patient, each available SPECT scan was rigidly 
aligned to the treatment planning CT. Rigid registrations were manually reviewed for 
accuracy. After registration, each voxel within the normal lung tissue contained both a dose 
value and function value (ie, normalized perfusion SPECT intensity). As in previous studies, 
rigid registration was performed instead of deformable registration to avoid uncharacterized 
errors that may be caused by low spatial resolution and unmatched breathing states between 
the SPECT/CT and planning CT images.
Normalization
To account for varying absolute intensity in SPECT scans taken across different time points 
and patients, the raw intensity value in each voxel was normalized. Because minimal 
functional changes are expected in low-dose regions, the functional normalization constant 
was determined as the average intensity in the functioning region (ie, all voxels >10% of 
maximum intensity) of the contralateral lung that received less than 5 Gy. Normalized 
intensity signal in any voxel is a relative measure of the local perfusion compared with the 
average functional value in unaffected tissue.
Data processing
To reduce the well-documented effect of 99mTc aerosol-trapping artifacts in patients with 
obstructive airway disease (47, 48), any voxel with an intensity value greater than 3 standard 
deviations above the mean intensity of the high-functioning lung region (ie, all voxels >50% 
of maximum intensity) was excluded. On average, 0.3% of the perfusion voxels were 
excluded from the normal lung volume.
Dose-function response
In this study, normalized perfusion intensity was applied directly as a surrogate for local 
lung function. To characterize each patient’s dose-function response over time, the 
normalized intensity in each voxel at the Mid-Tx, 3Month Post-Tx, and 1Year Post-Tx time 
points was compared to the normalized intensity in the same voxel at baseline:
δ f , t, j, i = f i, t
ℕ − f i, t = 0
ℕ (1)
Rocky Owen et al. Page 4
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2019 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
where f i, t = 0
ℕ
 is the normalized functional intensity signal in the ith voxel at time point t = 
{0 = baseline; 1 = Mid - tx ;2 = 3Month Post - tx;3 = 1Year Post – tx}. Dose bins of 5 Gy 
increments were used to tally the average functional change.
Patient-specific dose-function response modeling
To account for interdependencies within an individual patient’s dose-function response, the 
3-parameter logistic model described by Scheenstra et al (36) was expanded to allow for a 
patient-specific asymptote (αj, maximum possible reduction) and midpoint (μj; ie, the dose 
at which 50% of the maximum reduction occurs). This is a common analytic approach for 
correlated data and is also called a nonlinear mixed effects model, which refers to the 
mixture of population-and patient-specific parameters (49). As such, the reduction in 
baseline intensity for patient j at dose bin i is modeled as
Patient − specific logistic model:
α j
1 + e
− μ j − di /γ
(2)
A non-patient-specific (ie, population-averaged) inverse of the dose-effect slope at midpoint 
(γ) was set for all patients because of instability in fitting a patient-specific slope parameter. 
Using Equation 2, each patient’s average dose-function response data points were fit to 
obtain the patient-specific model parameters. Because the patient-specific effects are 
assumed to be centered around global means, the population-average midpoint (μ) and 
maximum possible reduction (α) were calculated by averaging the patient-specific model 
parameters obtained from the cohort. As such, the population-level model takes the 
following form:
Population − level logistic model: α
1 + e
− μ − di /γ
(3)
where di is the dose at the center of dose bin i. By allowing each patient’s dose-function 
response to be represented through a logistic function, the derived population-averaged 
logistic model better represents a patient’s coherent functional reduction over all dose bins.
The patient-specific logistic function was further modified to characterize dose response 
stratified by baseline intensity, as shown:
Stratified patient − specific model:
α j + ωk
1 + e
− μ j − di /γ
(4)
where k denotes the baseline intensity group, and αj + ωkdenotes the patient-specific 
asymptote for voxels in group k. For identifiability, ω4 was set to zero. The model shown in 
Equation 3 was used to describe the population-level response in each functional category. 
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Voxels were grouped with respect to baseline perfusion. Specifically, the groups included all 
voxels with baseline intensity, expressed as a percent of the maximum normal-tissue 
intensity, in the following ranges:
k = 1:10% to 30% o f baseline max; k = 2:30% to 50%; k = 3:50% to 75%; k = 4 :> 75%
Voxels below 10% of the maximum intensity were excluded from the analysis on the basis 
of the low number of counts. The 4 functional categories, which roughly correspond to 
quartiles, were chosen before performance of the statistical analysis.
The standard deviation in the reduction of function from baseline was allowed to vary with 
the number of voxels:
Standard deviation: σ mi j
λ (5)
where mij is the number of voxels in dose bin i for patient j, σ is a scale parameter that 
describes the deviation between the patient-specific parameters and their population-level 
means, and λ modifies the deviation based on the number of voxels in that dose bin. 
Typically λ is negative, which corresponds to a reduction in variance with an increasing 
number of voxels. These models were fit using the nlme package in R (50).
Results
Voxelwise reduction in normalized perfusion intensity was modeled using a patient-specific 
logistic function. Functional reduction was measured and modeled as the decrease in 
normalized perfusion intensity, meaning a δf;t;j;i of −0.5 signifies a reduction of +0.5 
normalized perfusion intensity units in that voxel. The presented models are graphically 
represented accordingly. For each patient, a normalized intensity of 1.0 signifies the average 
perfusion intensity of functioning voxels in the low-dose region of the contralateral lung. 
The population-level model parameters and standard deviations describing dose-perfusion 
response for the conventional RT and SBRT cohorts at each imaging time point are listed in 
Tables 2 and 3.
Dose-perfusion response for well-perfused voxels
Only well-perfused voxels were considered for the patient-specific and population-level 
dose-response curves shown in Fig. 1. The color data points represent the average functional 
change in that dose bin for each patient. Each individual patient’s data points are coherently 
modeled, as shown by the color-matched, shaded lines, using the logistic function shown in 
Equation 2. The patient-specific models are used to develop the bolded population-level 
dose-function response curves, as described by Equation 3. The population-level model fits 
and the associated uncertainty are explicitly tabulated in Table 2 and graphically shown in 
Fig. 2A. The shaded 95% confidence intervals are a function of both the spread in the 
distribution of patientspecific responses and the number of voxels contributing to the data, as 
shown in Equation 5. A significant longitudinal increase in perfusion reduction is clearly 
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observed, suggesting that lung function continues to degrade up to 1 year post-treatment. 
The maximal possible reduction asymptote ranged from approximately 30 to 60 Gy (EQD2), 
depending on the time point and treatment type. The patientspecific population-level models 
were compared with the population-level voxel-weighted average data points and non-
patient-specific logistic models (ie, simply fitting Equation 3 to the population-averaged data 
points), as shown in Fig. 2B.
Stratified dose-perfusion response for normalized baseline intensity >10% of the maximum
The patient-specific voxelwise reduction in normalized perfusion intensity with respect to 
planned dose was modeled for each stratified baseline intensity level using Equation 4. The 
population-level models can be interpreted as a prediction for voxelwise functional maximal 
reduction in each voxel group is longitudinally increasing (ie, ω1 < ω2 < ω3< ω4 = 0), and at 
the 3- and 12-month post-treatment time points, the confidence intervals for each parameter 
are nonoverlapping. This trend between perfusion reduction and baseline function in both 
cohorts suggests that higher functioning voxels at baseline are damaged at a greater rate than 
lower functioning voxels.
Discussion
This study quantified the voxelwise reduction in perfusion during and after radiation 
treatment by measuring the longitudinal change in normalized SPECT intensity, similar to 
methods in previous works. However, this analysis aimed to enhance the characterization of 
personalized functional changes by applying a patient-specific modeling approach that 
explicitly accounts for interdependencies within an individual patient’s dose-function 
response. Using this methodology, population-averaged dose-function response curves and 
their uncertainties were calculated for patients with NSCLC undergoing conventional RT 
and SBRT.
From age to chemotherapy to comorbidities, many patient-, treatment-, and disease-related 
factors explicitly affect an individual’s dose-function response (51–53). Each patient has a 
unique signature that inherently creates a distinct treatment response curve. As such, the 
voxels and the corresponding dose effect from one patient are more closely related to each 
other than to voxels from a different patient. Although the dose effect has classically been 
modeled by fitting population-averaged data points, it is proposed that a patient-specific 
model can more accurately describe the coherent dose-function response in an individual 
patient.
Logistic models have classically been used to describe dose-effect relations for cell survival. 
Boersma et al first proposed using the logistic model to describe changes in vascular 
subunits within the lung (31). Scheenstra et al recently showed that local functional changes 
in patients undergoing SBRT were best represented through a logistic model driven by 3 
parameters: (1) maximal reduction effect (asymptote); (2) dose to obtain 50% of maximal 
effect (midpoint); and (3) slope of the linear dose effect (36). However, because a patient’s 
signature effects the dose-function response over all dose bins, there is an inherent 
correlation among data points contributed by each patient. As a consequence of Jensen’s 
inequality, averaging each dose bin across patients would introduce bias in the resulting 
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estimated population-average curve (54). Therefore, a mixed-effects nonlinear regression 
model was used in this analysis to allow for a patient-specific maximal effect and midpoint 
dose, as shown in Equation 2. With this approach, each patient’s dose-perfusion response 
assumed a unique form, and population-level trends were derived, as shown in Fig. 1. With 
application of a logistic function to each individual patient’s data (as opposed to averaging 
each dose bin separately), the derived population-level model will better estimate the dose-
function response for a future, unknown patient.
Only minimal reductions in the high-dose regions were observed during treatment, whereas 
increasing longitudinal reductions occurred in these same areas after treatment. Furthermore, 
both patients undergoing conventional RT and those receiving SBRT consistently reached an 
asymptote in functional reduction near the target dose, suggesting that the maximal 
reduction effect occurs at a lower dose in conventionally fractionated RT. Although nearly 
all patients exhibit perfusion reduction at 3Month Post-Tx, 3 patients in both the 
conventional RT and SBRT cohorts exhibit markedly better response at 1Year Post-Tx than 
the rest of their cohort. This suggests a recovery pathway and illustrates the need for patient-
specific modeling.
Random effects were assumed to vary around population-level global means. Standard 
deviations were calculated to account for both the deviation from the mean and the statistical 
uncertainty associated with each data point. Therefore, the 95% confidence intervals 
represent the bounds of measured dose response for the conventional RT and SBRT cohorts. 
Analogously, these intervals can be interpreted as the uncertainty in predicting the voxelwise 
reduction in function from an unknown patient given the planned dose.
Previous works have mostly focused on analyzing functional response in well-perfused and 
well-ventilated regions. This focus stems from the idea that limiting dose to functioning lung 
can reduce toxicity by maintaining a patient’s functional reserve. However, the well-
perfused regions have not been consistently defined and only consist of a small portion of 
the lung receiving a high dose. This study modeled the well-perfused dose response for 
comparison with previous modeling techniques, as shown in Fig. 2B. However, this is the 
first study to differentially characterize dose-function response-based on pretreatment 
functional status-across all functioning voxels. Although deviations from the population-
level models are observed, the consistent differential treatment response suggests that 
initially higher functioning voxels exhibit a higher rate of perfusion loss, as shown in Fig. 3. 
Functional categorizations were chosen based on guidance from previous work (20, 33). 
Furthermore, the ranges were kept broad to ensure sufficient normal lung volume and 
limited statistical uncertainty in each category. However, because these categorizations were 
arbitrarily selected to represent functional capabilities, the bins may distinguish between 
regions that are not meaningfully different in their ability to exchange gas. Our results 
suggest that the voxelwise reduction in perfusion is a nonlinear function of baseline 
perfusion, in addition to being a nonlinear function of dose, which makes numerical fitting 
of this model substantially more difficult.
The amount of reperfusion has been shown to be directly proportional to perfusion 
deficiency (33), suggesting that perfusion reduction in initially poorly functioning regions is 
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diminished by a reperfusion effect that is inversely proportional to baseline intensity. The 
response was quantified in all functioning voxels because it is hypothesized that any portion 
of lung that is functioning at baseline can consequently become damaged and contribute to 
the loss of functional reserve. Future studies aim to further investigate the reperfusion effect 
and alternatively model the potential for functional improvement.
Although SPECT/CT is generally considered the gold standard for functional lung imaging, 
challenges regarding limited spatial resolution and presence of artifacts have been well 
documented. Because each frame of the SPECT image is acquired over a time period that 
typically encompasses several cardiac and breathing cycles, physiological motion will lead 
to spatial blurring of the signals. Although this may introduce errors in individual voxel 
intensities, the large binning of voxels reduced the impact of decreased spatial resolution. 
Average functional change was tallied within 5 Gy isodose volumes (ie, dose bins) such that 
numerous voxels contribute within each region. Although the use of rigid registration for 
functional image characterization can result in uncertainties, especially in areas of large 
motion and deformation, deformable image registration has typically not been applied to 
SPECT imaging because of low spatial resolution. Future studies using SPECT images may 
be improved by adjusting the acquisition parameters to better match the breathing states 
between the SPECT/CT and the planning CT image.
In many functional imaging modalities, such as SPECT/ CT, normalization is required to 
quantitatively analyze longitudinal change. Most prior studies analyzing perfusion changes 
using SPECT/CT have normalized intensities using the average value of the functioning 
voxels in the low-dose region of the contralateral lung (31, 34, 35). Although the specific 
definition of the low-dose region has varied, the technique is generally well accepted 
because minimal functional changes are expected in voxels receiving a low dose. We have 
yet to apply a patientspecific modeling approach to the contralateral lung, but this 
assumption was supported by the finding that the population-averaged functional change in 
the contralateral lung did not decrease significantly below 15 Gy, as shown in Fig. E1 
(available online at www.redjournal.org).
Because these clinical data were gathered between 2007 and 2013, patients were treated 
with a conventionally fractioned 3-dimensional conformal RT approach instead of the 
modern intensity modulated RT techniques currently used in the clinic. Many of these 
patients who received 3-dimensional conformal treatment would now be treated with 
volumetric modulated arc therapy, which would further change the dose-volume histogram 
profile. In an attempt to standardize the radiation effect between the treatment fractionation 
schemes, all doses were converted to EQD2 dose values. Furthermore, although some 
patient falloff occurred at the 3- and 12-month time points, we would not expect this loss of 
data to depend on the patient’s unobserved voxelwise dose-response curve; therefore, it 
should not cause bias in our estimated regression coefficients.
By characterizing the patient-specific dose-function response in all baseline functioning 
voxels, this work provides specific population-level estimates for the expected voxelwise 
reduction in perfusion at Mid-Tx, 3Month Post-Tx, and 1Year Post-Tx. These models allow 
for enhanced prediction of personalized functional damage by developing the population-
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level response through individual patient assessment and by segmenting the expected 
functional reduction based on a patient’s pre-treatment functional status. In theory, by 
applying the generated doseresponse incidence models, the cumulative functional lung 
damage for an unknown patient could be predicted and used to support functional-guided RT 
plans by weighting voxels based on their risk of functional damage.
Conclusions
A patient-specific modeling approach was applied to quantify the dose-function response 
using perfusion SPECT/CT images in patients with NSCLC undergoing conventional RT 
and SBRT. By deriving functional response from patient-specific assessment, the 
population-level models presented in this analysis can be used to better predict functional 
lung damage in an unknown patient. Differential treatment responses were observed based 
on the functional status of the voxel at baseline, suggesting that the highest functioning 
voxels are damaged at the highest rate. Although further refinement is required to implement 
personalized predictions of functional damage in the clinic, this work provides a simple 
methodology, applicable to any functional imaging modality, to more accurately model 
dose-function response.
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Summary
By quantifying the heterogeneous distribution of lung function prior to treatment, 
personalized radiation therapies have the potential to limit functional damage and reduce 
toxicity. However, a limited understanding of the normal-tissue response to radiation has 
hindered the incorporation of functional information in treatment planning. This study 
applied a patient-specific modeling approach to enhance characterization of the dose-
function response in non-small cell lung cancer patients treated with conventionally 
fractionated radiation therapy and stereotactic body radiation therapy. In addition, the 
dose-function response was further stratified by baseline intensity, suggesting that 
initially well-perfused voxels are damaged at the highest rate.
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Fig. 1. 
Individual patient dose-response bin averages (colored points) and patient-specific model fits 
(colored lines) overlaid with the population-level model fit (solid) for initially well-perfused 
voxels. Abbreviations: Conventional Z conventional radiation therapy; SBRT Z stereotactic 
body radiation therapy. (A color version of this figure is available at www.redjournal.org.)
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Fig. 2. 
(A) Dose-perfusion response at mid-treatment (Mid-Tx) (green), 3 months post-treatment 
(3Month Post-Tx) (red), and 1 year post-treatment (1Year Post-Tx) (purple), fit using a 
patient-specific logistic model. The 95% confidence intervals are represented by the shaded 
region. (B) Patient-specific logistic model fits (solid lines) compared with the voxel-
weighted average data (points) and non-patient-specific logistic model fits (shaded lines). 
Abbreviations: Conventional Z conventional radiation therapy; SBRT Z stereotactic body 
radiation therapy. (A color version of this figure is available at www.redjournal.org.)
Rocky Owen et al. Page 16
Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2019 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. 
Stratified dose-perfusion response for voxels in each normalized baseline intensity level: 
10% to 30% (red), 30% to 50% (orange), 50% to 75% (green), and >75% (blue) of the 
maximum intensity. Abbreviations: Conventional = conventional radiation therapy; SBRT Z 
stereotactic body radiation therapy. (A color version of this figure is available at 
www.redjournal.org.)
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Table 1
Patient characteristics
Conventional RT cohort (n = 60) SBRT cohort (n = 21)
SPECT scans available (n)
    Baseline 60 21
    Mid-Tx 54 20
    3Month Post-Tx 37 14
    1Year Post-Tx 19 7
Age (y)
    Median 65 72
    Range 39–85 53–83
Sex (n)
    Male 47 13
    Female 13 8
Volume (lung GTV) (cm3)
    Median 3842 3901
    Range 1837–9540 1808–6489
Mean dose (lung GTV) (Gy)
    Median 13.1 7.4
    Range 3.0–21.2 3.7–16.2
Abbreviations: 1Year Post-Tx = 1 year post-treatment; 3Month Post-Tx = 3 months post-treatment; GTV Z gross tumor volume; Mid-Tx = 
midcourse treatment; SBRT = stereotactic body radiation therapy; SPECT Z single-photon emission computed tomography.
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Table 2
Population-level model parameters and standard deviations describing the expected dose-function response in 
well-perfused voxels at baseline (95% confidence intervals)
RT modality/time point N E[αj] = α sd[αj] E[μj] = μ sd[μj]
Conventional RT/Mid-Tx 54 0.22 (0.16–0.27) 0.21 (0.17–0.26) 9.8 (4.1–15.5) 17.9 (13.9–23.1)
Conventional RTOMonth Post-Tx 37 0.72 (0.62–0.81) 0.28 (0.22–0.35) 18.2 (14.4–22.1) 10.9 (8.2–14.4)
Conventional RT/lYear Post-Tx 19 1.00 (0.80–1.21) 0.44 (0.28–0.69) 21.8 (8.9–34.7) 28.1 (19.8–40.0)
SBRT/Mid-Tx 20 0.24 (0.12–0.37) 0.27 (0.18–0.40) 45.0 (28.9–61.2) 35.3 (24.5–50.9)
SBRT/3Month Post-Tx 14 0.56 (0.46–0.66) 0.19 (0.13–0.27) 13.9 (4.4–23.3) 17.0 (10.8–26.7)
SBRT/1 Year Post-Tx 7 0.86 (0.56–1.15) 0.39 (0.23–0.67) 21.8 (18.3–25.3) -
RT modality/time point γ σ λ
Conventional RT/Mid-Tx 5.4 (4–0-6.8) 0.22 (0.19–0.26) −0.11 (−0.13 to −0.08)
Conventional RTOMonth Post-Tx 9.6 (8.5–10.7) 0.32 (0.24–0.41) −0.13 (−0.17 to −0.10)
Conventional RT/1Year Post-Tx 10.3 (8.7–12.0) 0.16 (0.10–0.25) −0.03 (−0.10 to 0.03)
SBRT/Mid-Tx 14.0 (11.5–16.5) 0.10 (0.09–0.11) −0.06 (−0.07 to −0.04)
SBRTOMonth Post-Tx 12.1 (9.9–14.4) 0.11 (0.10–0.13) −0.01 (−0.04 to 0.01)
SBRT/1Year Post-Tx 20.4 (16.4–24.3) 0.12 (0.09–0.15) 0.03 (−0.03 to 0.08)
Abbreviations: 1Year Post-Tx = 1 year post-treatment; 3Month Post-Tx = 3 months post-treatment; Mid-Tx = midcourse treatment; SBRT Z 
stereotactic body radiation therapy.
Models with “-“ listed in the sd[μj] column were unable to converge using patient-specific midpoints; thus, the same population-level midpoint was 
given to all patient in that cohort.
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Table 3
Population-level model parameters and standard deviations describing the expected dose-function response 
stratified by functional categorization at baseline (95% confidence intervals)
RT modality/time point E[αj] = α sd[αj] E[μj] = μ sd[μj] γ
Conventional RT/Mid-Tx 0.71 (−0.25 to 
1.66)
− 46.6 (−102.6 to 
195.8)
- 53.8 (−5.4 to 
113.1)
Conventional RT/3Month Post-Tx 1.26 (1.19–1.33) 0.16 (0.13–0.21) 25.1 (20.6–29.6) 13.2 (10.3–16.9) 13.0 (11.9–14.1)
Conventional RT/1Year Post-Tx 1.23 (1.10–1.37) 0.23 (0.16–0.32) 17.9 (14.9–20.9) - 15.4 (12.6–18.1)
SBRT/Mid-Tx 0.51 (0.43–0.59) 0.13 (0.09–0.18) 34.2 (19.1–49.3) 58.4 (41.5–75.2)
SBRT/3Month Post-Tx 0.86 (0.77–0.94) 0.16 (0.11–0.23) 14.6 (4.0–25.1) 19.8 (13.4–29.2) 13.3 (11.6–15.1)
SBRT/1Year Post-Tx 1.19 (1.02–1.36) 0.22 (0.13–0.38) 26.0 (14.1–37.9) 15.8 (9.1–27.2) 15.1 (13.3–16.9)
RT modality/time point ω1 ω2 ω3 σ λ
Conventional RT/Mid-Tx −0.90 (0.32 to 
−2.12)
−0.72 (0.26 to 
−1.69)
−0.45 (0.16 to 
−1.07)
0.51 (0.46–0.57) −0.15 (−0.17 to 
−0.14)
Conventional RT/3Month Post-Tx −1.17 (−1.13 to –
1.22)
−0.89 (−0.85 to 
−0.93)
−0.53 (−0.49 to 
−0.56)
0.29 (0.25–0.32) −0.10 (−0.12 to 
−0.08)
Conventional RT/1Year Post-Tx −1.15 (−1.06 to 
−1.24)
−0.85 (−0.77 to 
−0.93)
−0.53 (−0.46 to 
−0.59)
0.44 (0.37–0.53) −0.12 (−0.14 to 
−0.09)
SBRT/Mid-Tx −0.57 (−0.50 to 
−0.63)
−0.43 (−0.38 to 
−0.49)
−0.29 (−0.25 to 
−0.33)
0.21 (0.20–0.22) −0.09 (−0.10 to 
−0.08)
SBRT/3Month Post-Tx −0.83 (−0.81 to 
−0.86)
−0.58 (−0.55 to 
−0.60)
−0.32 (−0.30 to 
−0.35)
0.17 (0.16–0.18) −0.07 (−0.08 to 
−0.05)
SBRT/1Year Post-Tx −1.04 (−0.98 to 
−1.09)
−0.69 (−0.64 to 
−0.73)
−0.38 (−0.33 to 
−0.43)
0.27 (0.25–0.30) −0.13 (−0.14 to 
−0.11)
Abbreviations: 1Year Post-Tx = 1 year post-treatment; 3Month Post-Tx = 3 months post-treatment; GTV = gross tumor volume; Mid-Tx = 
midcourse treatment; SBRT = stereotactic body radiation therapy.
Models with “-" listed in the sd[μj] column were unable to converge using patient-specific midpoints; thus, the same population-level midpoint was 
given to all patient in that cohort. The number of patients contributing to each model is the same as shown in Table 2.
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